RNAi-Induced Gene Silencing against Chikungunya and COVID-19: What Have We Learned So Far, and What Is the Way Forward?

RNAi-Induced Gene Silencing against Chikungunya and COVID-19: What Have We Learned So Far, and What Is the Way Forward?

Publication date: Sep 20, 2024

RNA interference (RNAi) is a process in which small RNA molecules (such as small interfering RNAs or siRNAs) bind to specific messenger RNAs (mRNAs), leading to its degradation and inhibition of protein synthesis. Our studies have shown that RNAi can effectively silence genes involved in the replication of the Chikungunya virus (CHIKV) in cells. However, these investigations were performed only in laboratory settings and have yet to be tested in human clinical trials. Researchers need to conduct more research to determine the safety and efficacy of RNAi-based therapies as a therapeutic agent to treat viral infections. In this review, the history of evolution of siRNA as an inhibitor of protein synthesis, along with its current developments, is discussed based on our experience. Moreover, this review examines the hurdles and future implications associated with siRNA based therapeutic approaches.

Open Access PDF

Concepts Keywords
Laboratory Animals
Mrnas Chikungunya
Silence Chikungunya Fever
Therapeutic Chikungunya virus
Virus COVID-19
Gene Silencing
Humans
RNA Interference
RNA interference
RNA, Small Interfering
RNA, Small Interfering
SARS-CoV-2
SARS-CoV-2
siRNA
Virus Replication

Original Article

(Visited 1 times, 1 visits today)